Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Teva
Chubb
Mallinckrodt
Farmers Insurance
Moodys
Harvard Business School
Cerilliant
Baxter

Generated: July 19, 2018

DrugPatentWatch Database Preview

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir and what is the scope of dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir freedom to operate?

Dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir has five hundred and twenty-five patent family members in fifty-one countries.

One supplier is listed for this compound.
Summary for DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patents and Regulatory Information for DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 ➤ Sign Up ➤ Sign Up
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,853,176 Methods for treating HCV ➤ Sign Up
8,969,357 Methods for treating HCV ➤ Sign Up
9,452,194 Methods for treating HCV ➤ Sign Up
8,332,661 Method and apparatus for prevention of tampering, unauthorized use, and unauthorized extraction of information from microdevices ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
7 50010-2015 Slovakia ➤ Sign Up PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119
2015013,C2203431 Lithuania ➤ Sign Up PRODUCT NAME: DASABUVIRAS; REGISTRATION NO/DATE: EU/1/14/983 20150115
/2015 Austria ➤ Sign Up PRODUCT NAME: PARITAPREVIR, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER ANNEHMBARER ESTER DAVON; REGISTRATION NO/DATE: (MITTEILUNG VOM 19.1.2015) EU/1/14/982 20150115
2015013 Lithuania ➤ Sign Up PRODUCT NAME: DASABUVIRUM; REGISTRATION NO/DATE: EU/1/14/983 20150115
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
US Department of Justice
Cerilliant
Farmers Insurance
Argus Health
Fuji
Deloitte
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.